Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Fairly valued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Modest
Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Fairly valued vs peers
Very low or no dividends
Very poor margins and returns
A$ 0.02
About
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to...
About
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in...